Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Female
• Over 18 years old
• Breast cancer
• Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin.
Locations
Other Locations
Brazil
Hospital de Clinicas da Unicamp
RECRUITING
Campinas
Contact Information
Primary
Otavio Rizzi Coelho-Filho, MD, MPH, PhD
tavicocoelho@gmail.com
+55 19 3521-7755
Backup
Joaquim Barreto Oliveira, MD
jba.clinicamedica@gmail.com
+55 19 3521 7959
Time Frame
Start Date: 2024-01-30
Estimated Completion Date: 2026-08-30
Participants
Target number of participants: 80
Treatments
Experimental: Dapagliflozin
Standard chemotherapy treatment + Dapagliflozin 10mg/day.
Placebo_comparator: Placebo Group
Standard chemotherapy treatment + Placebo.
Related Therapeutic Areas
Sponsors
Leads: University of Campinas, Brazil